6533b85ffe1ef96bd12c1ac9
RESEARCH PRODUCT
Inhibition of Mitochondrial Function by Efavirenz Increases Lipid Content in Hepatic Cells
Victor M. VictorMilagros RochaJosé Manuel MoralesJuan V. EspluguesDaniel MonleonAna Blas-garciaDaniel BallesterosNadezda Apostolovasubject
CyclopropanesMaleEfavirenzAnti-HIV AgentsRespiratory chainMitochondria LiverPharmacologyBiologyMitochondrionNucleoside Reverse Transcriptase InhibitorRats Sprague-Dawleychemistry.chemical_compoundOxygen ConsumptionAMP-Activated Protein Kinase KinasesmedicineAnimalsHumansHepatologyAMPKLipid metabolismLipid MetabolismAdenosineLipidsBenzoxazinesRatschemistryBiochemistryAlkynesHepatocytesAdenosine triphosphateProtein Kinasesmedicine.drugdescription
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) widely used in human immunodeficiency virus (HIV) infection therapy. It has been associated with hepatotoxic effects and alterations in lipid and body fat composition. Given the importance of the liver in lipid regulation, we have evaluated the effects of clinically used concentrations of EFV on the mitochondria and lipid metabolism of human hepatic cells in vitro. Mitochondrial function was rapidly undermined by EFV to an extent that varied with the concentration employed; in particular, respiration and intracellular adenosine triphosphate (ATP) levels were reduced whereas reactive oxygen species (ROS) production increased. Results in isolated mitochondria suggest that the mechanism responsible for these actions was a specific inhibition of complex I of the respiratory chain. The reduction in energy production triggered a compensatory mechanism mediated by the enzyme adenosine monophosphate activated protein kinase (AMPK), the master switch of cellular bio-energetics. Fluorescence and nuclear magnetic resonance demonstrated a rapid intracellular increase of neutral lipids, usually in the form of droplets. This was prevented by the AMPK inhibitor compound C and by removal of fatty acids from the culture medium. These effects were not reproduced by Nevirapine, another NNRTI. EFV is clinically coadministered with two nucleoside reverse transcriptase inhibitors. Evaluation of one of the most common combination, EFV/Lamivudine/Abacavir, revealed that the effects of EFV on ROS production were enhanced. Conclusion: Clinical concentrations of EFV induce bioenergetic stress in hepatic cells by acutely inhibiting mitochondrial function. This new mechanism of mitochondrial interference leads to an accumulation of lipids in the cytoplasm that is mediated by activation of AMPK. (HEPATOLOGY 2010;52:115-125)
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2010-01-01 |